NCT02974621 is a Phase 2 clinical trial of Bevacizumab in Recurrent Glioblastoma, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT02974621?

NCT02974621 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT02974621?

Interventions in NCT02974621: Bevacizumab, Cediranib, Cediranib Maleate, Olaparib.

What condition does NCT02974621 study?

NCT02974621 studies Recurrent Glioblastoma.

Is NCT02974621 still recruiting?

NCT02974621 is currently active, enrolled. Last updated 3 August 2025.

Are results published for NCT02974621?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-08-03 · How we verify

NCT02974621

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Active, enrolled Phase 2 Results posted Last updated 3 August 2025

What this trial tests

Phase 2 trial testing Bevacizumab in Recurrent Glioblastoma in 70 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 December 2017

Primary endpoint
31 December 2022

17 July 2026

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	7 December 2017
Primary completion	31 December 2022
Estimated completion	17 July 2026
Sites	27 locations across United States

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Cediranib — full drug profile →
Cediranib Maleate
Olaparib (olaparib) — full drug profile →

Conditions studied

Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Progression-Free Survival at 6 Months Primary · 6 months

Progression-Free Survival (PFS) is defined as the time from randomization to progressive disease (PD) per Response Assessment in Neuro-Oncology (RANO) criteria, or death due to any cause, whichever occurs first. Participants alive without PD are censored at date of last disease evaluation. PD criteria: (A) 25% increase in sum of the products of perpendicular diameters of enhancing lesions (over best response or baseline if no decrease) on stable or increasing doses of steroids and/or one or more of the following: (B) Significant increase in T2/FLAIR non-enhancing lesion on stable or increasi

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	16	5 – 32
Arm B (Bevacizumab)	28	11 – 47

Progression Free Survival Secondary · Up to 3 years

Progression free survival is defined as the time from randomization until progressive disease or death from any cause.

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	118	63 – 173
Arm B (Bevacizumab)	92	45 – 142

Overall Survival (OS) Secondary · up to 3 years

Overall Survival (OS) is defined as the time from randomization to death due to any cause, or censored at date last known alive.

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	316	178 – 459
Arm B (Bevacizumab)	218	135 – 368

Incidence of Adverse Events (AE) Secondary · Up to 3 years

The grade of adverse events be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events 5.0. The incidence of an adverse event at a particular grade is the number of patients who experienced that adverse event/grade.

Anemia

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	2
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	32
Arm B (Bevacizumab)	25

Leukopenia

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	1
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	33
Arm B (Bevacizumab)	25

Neutropenia

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	1
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	1
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	32
Arm B (Bevacizumab)	25

Lymphopenia

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	2
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	32
Arm B (Bevacizumab)	25

Thrombocytopenia

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	1
Arm A (Olaparib, Cediranib Maleate)	1
Arm B (Bevacizumab)	1
Arm A (Olaparib, Cediranib Maleate)	33
Arm B (Bevacizumab)	23

Hypertension

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	3
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	31
Arm B (Bevacizumab)	25

Heart Failure

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	1
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	33
Arm B (Bevacizumab)	25

Transaminitis

Group	Value	95% CI
Arm A (Olaparib, Cediranib Maleate)	1
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	0
Arm B (Bevacizumab)	0
Arm A (Olaparib, Cediranib Maleate)	33
Arm B (Bevacizumab)	25

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 3 years. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm A (Olaparib, Cediranib Maleate)

Serious: 16/34 (47%)

Deaths: 31/35

Arm B (Bevacizumab)

Serious: 13/25 (52%)

Deaths: 23/35

Serious adverse events (24 terms)

Reaction	System	Arm A (Olaparib, Cediranib…	Arm B (Bevacizumab)
Seizure	Nervous system disorders	—	—
Neoplasms - Other - Disease Progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Heart Failure	Cardiac disorders	—	—
Death, not otherwise specified	General disorders	—	—
Fever	General disorders	—	—
Esophagitis	Gastrointestinal disorders	—	—
Neutrophil count decreased	Investigations	—	—
White blood cell decreased	Investigations	—	—
Dehydration	Metabolism and nutrition disorders	—	—
Muscle weakness lower limb	Musculoskeletal and connective tissue disorders	—	—
Somnolence	Nervous system disorders	—	—
Muscle weakness right-sided	Musculoskeletal and connective tissue disorders	—	—
Muscle weakness left-sided	Musculoskeletal and connective tissue disorders	—	—
Confusion	Psychiatric disorders	—	—
Erythema multiforme	Skin and subcutaneous tissue disorders	—	—
Thromboembolic event	Vascular disorders	—	—
Cholecystitis	Hepatobiliary disorders	—	—
Infections & infestations - Other - Upper Respiratory Infection	Infections and infestations	—	—
Joint infection	Infections and infestations	—	—
Fall	Injury, poisoning and procedural complications	—	—
Metabolism and nutrition - Other - Diabetes Insipidus	Metabolism and nutrition disorders	—	—
Dysphasia	Nervous system disorders	—	—
Intracranial hemorrhage	Nervous system disorders	—	—
Syncope	Nervous system disorders	—	—

Other adverse events (175 terms — click to expand)

Reaction	System	Arm A (Olaparib, Cediranib…	Arm B (Bevacizumab)
Urinary tract infection	Infections and infestations	—	—
Hypertension	Vascular disorders	—	—
Diarrhea	Gastrointestinal disorders	—	—
Anorexia	Metabolism and nutrition disorders	—	—
Fatigue	General disorders	—	—
Nausea	Gastrointestinal disorders	—	—
ALT increased	Investigations	—	—
Platelet count decreased	Investigations	—	—
Gait disturbance	General disorders	—	—
Headache	Nervous system disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Fall	Injury, poisoning and procedural complications	—	—
Hypothyroidism	Endocrine disorders	—	—
Proteinuria	Renal and urinary disorders	—	—
Anemia	Blood and lymphatic system disorders	—	—
Dizziness	Nervous system disorders	—	—
Seizure	Nervous system disorders	—	—
Weight loss	Investigations	—	—
Hyponatremia	Metabolism and nutrition disorders	—	—
Lymphocyte count decreased	Investigations	—	—
Neutrophil count decreased	Investigations	—	—
White blood cell decreased	Investigations	—	—
Confusion	Psychiatric disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Dyspepsia	Gastrointestinal disorders	—	—
Hematuria	Renal and urinary disorders	—	—
Hypokalemia	Metabolism and nutrition disorders	—	—
Mucositis oral	Gastrointestinal disorders	—	—
Muscle weakness left-sided	Nervous system disorders	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—
AST increased	Investigations	—	—
Blood bilirubin increased	Investigations	—	—
Dysphagia	Gastrointestinal disorders	—	—
Dysphasia	Nervous system disorders	—	—
Edema limbs	General disorders	—	—
Generalized muscle weakness	Musculoskeletal and connective tissue disorders	—	—
Hoarseness	Respiratory, thoracic and mediastinal disorders	—	—
Hyperglycemia	Metabolism and nutrition disorders	—	—
Hyperkalemia	Metabolism and nutrition disorders	—	—

Most-reported serious reactions: Seizure, Neoplasms - Other - Disease Progression, Heart Failure, Death, not otherwise specified, Fever, Esophagitis, Neutrophil count decreased, White blood cell decreased.

Data from ClinicalTrials.gov NCT02974621 adverse events section.

Sponsor's own description

This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, et al · · 2018 · cited 612× · PMID 29669750 · DOI 10.1124/pr.117.014944
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, Lafortune F, et al · · 2021 · cited 532× · PMID 34302977 · DOI 10.1016/j.phrs.2021.105780
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, et al · · 2024 · cited 147× · PMID 38473776 · DOI 10.3390/ijms25052529
Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment.
Delgado-Martín B, Medina MÁ. · · 2020 · cited 129× · PMID 32382477 · DOI 10.1002/advs.201902971
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C, Lawrie TA, Rogozińska E, Kernohan A, et al · · 2021 · cited 105× · PMID 34559423 · DOI 10.1002/14651858.cd013579.pub2
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies.
Paolillo M, Boselli C, Schinelli S. · · 2018 · cited 95× · PMID 29337870 · DOI 10.3390/brainsci8010015

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Recurrent Glioblastoma

Currently open trials in the same condition.

NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07209241 — Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM · Phase 1 · recruiting
NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02974621 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 3 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02974621.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing